Subscribe To
IMRX / Immuneering to Present Preclinical Data on IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
IMRX News
By GlobeNewsWire
October 4, 2023
Immuneering to Present Preclinical Data on IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for more_horizontal
By Seeking Alpha
July 7, 2023
Immuneering Corp.: Early Stage Promise, But Long-Term Investment
IMRX is an early-stage company with promising science. They do not have clinical efficacy data. While I like the company, be warned that this is going more_horizontal
By Zacks Investment Research
July 5, 2023
Wall Street Analysts Think Immuneering Corporation (IMRX) Could Surge 103.8%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 103.8% in Immuneering Corporation (IMRX). While the effective more_horizontal
By Zacks Investment Research
May 4, 2023
Immuneering Corporation (IMRX) Reports Q1 Loss, Misses Revenue Estimates
Immuneering Corporation (IMRX) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares more_horizontal
By Zacks Investment Research
April 11, 2023
Immuneering Corporation (IMRX) Surges 18.5%: Is This an Indication of Further Gains?
Immuneering Corporation (IMRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate rev more_horizontal
By Zacks Investment Research
March 27, 2023
Wall Street Analysts Believe Immuneering Corporation (IMRX) Could Rally 102.51%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 102.5% in Immuneering Corporation (IMRX). While the effective more_horizontal
By The Motley Fool
March 24, 2023
Why Shares of Immuneering Jumped This Week
Immuneering is a clinical-stage biopharmaceutical that focuses on oncology therapies. The company's lead therapy is in a phase 1/2a trial. more_horizontal
By Zacks Investment Research
March 23, 2023
Immuneering Corporation (IMRX) Soars 16.9%: Is Further Upside Left in the Stock?
Immuneering Corporation (IMRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions mig more_horizontal